Joint Clinical Trials Office
Communicating Options for Advanced Breast Cancer Support and Treatment (COAST)
Study Status:
Open to Enrollment
Primary Investigator:
Date: June 16, 2026
NRG-GI011: A PHASE III RANDOMIZED TRIAL OF DOSE ESCALATED RADIATION IN LOCALLY ADVANCED PANCREAS CANCER (LAPC) PATIENTS (LAP100)
Study Status:
Open to Enrollment
Primary Investigator:
Date: June 5, 2026
GALAXY: Generating Advancements through Longitudinal Analysis in X and Y Variations
Study Status:
Open to Enrollment
Primary Investigator:
Date: June 5, 2026
BioHealx Anal Fistula Device Post Market Surveillance Study
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 29, 2026
REPOWER: "Real-world Evaluation of Patient Outcomes and Experiences with Ribociclib Early Adopters: A Hybrid Study with Prospective Patient-reported Outcomes and Retrospective Clinical Chart Review"
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 29, 2026
A Phase 2/3 Multicenter Randomized Open-Label Study Evaluating the Efficacy & Safety of Etentamig and Daratumumab Compared to Daratumumab, Lenalidomide, and Dexamethasone in Subjects with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 29, 2026
Pathology and CT Microdosimetry of Eye90 Treated Hepatocellular Carcinoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 11, 2026
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants with Nonsegmental Vitiligo
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 11, 2026
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants with Nonsegmental Vitiligo
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 5, 2026
Pilot Randomized Trial of Health Coaching for People with Rheumatoid Arthritis to Improve Mental Well Being
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 1, 2026